Wednesday, 1 Apr 2026
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • ScienceAlert
  • White
  • VIDEO
  • man
  • Trumps
  • Season
  • star
  • Watch
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Promising BioNTech data on triple negative breast cancer treatment
Health and Wellness

Promising BioNTech data on triple negative breast cancer treatment

Last updated: December 15, 2024 8:21 am
Share
Promising BioNTech data on triple negative breast cancer treatment
SHARE

Researchers may have discovered a promising candidate for the next generation of immunotherapy drugs in the form of bispecific antibodies targeting two key proteins in cancer – PD1 or PD-L1 and VEGF. A recent small early trial presented at the San Antonio Breast Cancer Symposium by researchers working with BioNTech showcased positive results in patients with triple negative breast cancer using a bispecific compound called BNT-327. This compound, if further trials prove successful, could become a crucial part of treating not only triple negative breast cancer but potentially other types of cancer as well.

The development of bispecific antibodies targeting PD1 or PD-L1 and VEGF builds upon the groundbreaking discovery of checkpoint inhibitors in the 1990s. These inhibitors, such as Merck’s Keytruda, have revolutionized cancer treatment by stimulating the immune system to recognize and eliminate cancer cells. However, there is still room for improvement in this area. BioNTech co-founder and CMO Özlem Türeci believes that PD-L1 or PD1 and anti-VEGF bispecifics represent the next generation of checkpoint inhibitors that could further enhance cancer treatment.

The potential of bispecific antibodies targeting these proteins gained attention when Summit Therapeutics released data showing that their PD1 and VEGF bispecific antibody outperformed Keytruda in a Phase 3 trial for advanced lung cancer. While experts noted the impressive results, they also cautioned that further research is needed to determine if the drug can extend overall survival, a critical measure in oncology research.

This article highlights the significant progress being made in the field of immunotherapy and the potential impact of bispecific antibodies targeting PD1 or PD-L1 and VEGF. As researchers continue to explore and develop new treatments, the future of cancer therapy looks promising.

See also  Potent sweetener neotame found by researchers in popular vapes
TAGGED:BioNTechbreastcancerDatanegativepromisingTreatmenttriple
Share This Article
Twitter Email Copy Link Print
Previous Article Bernie Kaminski Invokes Decades Past Through Papier-Mâché Objects — Colossal Bernie Kaminski Invokes Decades Past Through Papier-Mâché Objects — Colossal
Next Article The sun may spit out giant solar flares more often than we thought The sun may spit out giant solar flares more often than we thought
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Longtime New Yorker walking on Central Park West is grazed by stray bullet in ‘terrifying’ ordeal

A 55-year-old woman, a longtime New Yorker, was grazed by a stray bullet while walking…

May 9, 2025

$2 million Southwest Airlines voucher scam ends with federal prison sentence for CPS teacher

Former CPS Teacher Sentenced to Prison in Southwest Airlines Voucher Scam (Image: CWBChicago) A former…

December 2, 2025

Oblivion Remastered Hype Proves Why an Elder Scrolls TV Series Must Happen

The storyline that follows involves betrayal, intrigue, and plenty of murder, with a twist ending…

April 29, 2025

All I Want for Christmas Is More Art Books

Thompson, whose own writing is as masterful as Amore's storytelling? In her review, Thompson delves…

December 15, 2025

Nebius Group (NBIS) Ends 5.4% Lower as $18-Billion Cloud Computing Deal Glow Fades

We've recently released a new article titled 10 Stocks Hit Harder than the Market. Nebius…

October 17, 2025

You Might Also Like

WHOOP Health Platform Gets Glitzy Investors, Makes Big Promises
Health and Wellness

WHOOP Health Platform Gets Glitzy Investors, Makes Big Promises

March 31, 2026
HSA industry’s lobbying push, MAHA’s rough stretch: D.C. Diagnosis
Health and Wellness

HSA industry’s lobbying push, MAHA’s rough stretch: D.C. Diagnosis

March 31, 2026
Elevance Health Latest Insurer To Shake Up Management Ranks
Health and Wellness

Elevance Health Latest Insurer To Shake Up Management Ranks

March 31, 2026
HSA firms boost lobbying to cash in on Trump’s Great Healthcare Plan
Health and Wellness

HSA firms boost lobbying to cash in on Trump’s Great Healthcare Plan

March 31, 2026
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?